bioengineer.org /6 days ago

Engineered Adeno-Associated Virus Enables Efficient In Vivo Immune Cell Programming

A directed-evolution adeno-associated virus capsid targeting CD7 achieves robust gene delivery and therapeutic chimeric antigen receptor cell engineering in living animal models.

Read source
newswire.com /6 days ago

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Re...

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...

Read source
cafepharma.com /1 month ago

CV Jan 31st

CV Jan 31st Anonymous (not verified) Fri, 10/16/2026 - 10:12 field_thread_url https://cafepharma.com/boards/threads/cv-jan-31st.706258/...

Read source
qchron.com /1 month ago

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager

Read source
newswire.com /1 month ago

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...

Read source
ch-aviation.com /1 month ago

SPARFELL Group reactivates San Marino AOC

This article is only available with a subscription for Commercial Aviation News, Operator & Airport Data

Read source
healio.com /1 week ago

ANGPTL4 inhibition appears to reduce triglycerides

CHICAGO — A monoclonal antibody that inhibits angiopoietin-like protein 4 was linked to triglyceride reduction at 12 weeks in adults with high triglycerides, researchers reported a...

Read source
newswire.com /1 week ago

Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds

Read source
qchron.com /1 week ago

Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...

Read source
seekingalpha.com /2 weeks ago

Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - Slideshow

Read source
seekingalpha.com /1 week ago

AEVEX Corp. (AVEX) Q3 2026 Earnings Call Transcript

Read source
seekingalpha.com /1 week ago

Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program - Slideshow

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.